Randomized Trialvery high evidence
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
Lancet (London, England)·August 24, 2024·PMID 39181597
Why it mattersThis analysis provides evidence that semaglutide reduces cardiovascular events in patients with established heart failure, a high-risk group often excluded from prior GLP-1 trials. It supports broader use in patients with both atherosclerotic disease and heart failure, regardless of ejection fraction.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled